drugset / Trial / NCT00029224

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

NCT00029224

Phase 4 Completed 500 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Timeline

Start
2001-10
Primary completion
2002-11
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 4 mg Intravenous